Stéphane Bancel

Bancel was born in 1972 and grew up in Marseille, France; his father was an engineer and his mother a doctor.⁠[1]

Bancel studied chemical and biomolecular engineering at École Centrale Paris, earning a Master of Engineering, and then continued his studies at the University of Minnesota.⁠[1][2]

The University of Minnesota alumni page lists him as a 1995 chemical engineering graduate of the College of Science and Engineering; Moderna’s investor relations page states that he holds a Master of Science in chemical engineering from the university.⁠[3][2]

Bancel’s first job was at the French diagnostics company bioMérieux, where he served as Asia-Pacific sales and marketing director; bioMérieux sponsored his MBA at Harvard Business School.⁠[1][2]

From July 2000 to March 2006 Bancel worked at the American pharmaceutical company Eli Lilly and CompanyEli Lilly and CompanyEli Lilly and Company (NYSE: LLY) is a U.S. pharmaceutical company founded in 1876 by Colonel Eli Lilly and headquartered in Indianapolis, Indiana.Open the full entry, in positions including Managing Director, Belgium, and Executive Director, Global Manufacturing Strategy and Supply Chain.⁠[2]

At 34 Bancel returned to bioMérieux as chief executive officer, a post he held for five years.⁠[1][2]

Bancel joined Moderna’s board in March 2011 and became chief executive officer that October; Flagship Pioneering describes him as president and founding CEO of the Flagship company. At the time Moderna was a loss-making start-up focused on messenger RNA (mRNA).⁠[2][4][1]

Bancel joined the venture creation firm Flagship Pioneering in 2013 as a Special Partner, advising its portfolio companies; Moderna’s investor relations page describes him as a Venture Partner at Flagship Pioneering.⁠[4][2]

Moderna went public in 2018; before the listing Bancel was known for his fundraising and was described as a “master fundraiser.”⁠[1]

Over the 2019 Christmas break, before the new coronavirus had a name, Bancel was tracking the outbreak in China. Moderna then became the first company in the United States to begin trials of an mRNA vaccine.⁠[1]

On December 18, 2020, the U.S. Food and Drug Administration issued an emergency use authorization for the Moderna COVID-19 Vaccine for individuals 18 years of age and older, the second COVID-19 vaccine authorized in the United States.⁠[5]

As of April 2021 Moderna’s shares had risen more than 500% since mid-March 2020, and the company was charging $33 to $37 per dose of its vaccine.⁠[1]

Bancel was named a Chevalier of the Légion d’honneur in 2022, was elected to the U.S. National Academy of Engineering in 2024 and was named to the 2026 ForbesForbesForbes is an American business media brand that began with Forbes magazine, founded by B.C. Forbes in 1917. It is known for rankings such as the Forbes 400, the World’s Billionaires list and 30 Under 30, and operates Forbes.com, ForbesLive events and licensed editions in 81 countries. Since 2014 a majority stake has been held by the Hong Kong investment group Integrated Whale Media; a 2021 plan to list on the New York Stock Exchange through a special purpose acquisition company was terminated in 2022. It is headquartered in Jersey City, New Jersey.Open the full entry 250 Builders List.⁠[2][4]

Bancel was the University of Minnesota’s 2023 commencement speaker, describing himself as “a kid from Marseille, France”; the university’s page quotes him: “If you surround yourself with mission-minded people, you will do great things.”⁠[3]

In August 2026 Merck & Co.Merck & Co.Merck & Co., Inc. is a global health care company headquartered in Rahway, New Jersey, that develops medicines and vaccines and is called MSD outside the United States and Canada.Open the full entry and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial: the individualized mRNA neoantigen therapy intismeran autogene (V940/mRNA-4157) combined with pembrolizumab met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival at a prespecified interim analysis, compared with pembrolizumab alone. The trial enrolled 1,137 patients with completely resected stage IIB–IV cutaneous melanoma; overall survival continues to be evaluated.⁠[6]

On September 2, 2026, the a16zAndreessen HorowitzAndreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz. It invests from the seed stage through the growth stage and provides operational support to its portfolio companies.Open the full entry YouTubeYouTubeYouTube is Google’s video-sharing and creator platform, founded in 2005 by Steve Chen, Chad Hurley, and Jawed Karim and acquired by Google in 2006. Built around video uploading, viewing, and creator earnings, the platform has developed Shorts, YouTube Music, Premium, YouTube TV, and products for children, and is headquartered in San Bruno, California, United States.Open the full entry channel published “Inside Moderna’s Biggest mRNA Test Since COVID,” in which Jorge CondeJorge CondeJorge Conde is a biotechnology entrepreneur and a general partner on the Bio + Health team at Andreessen Horowitz (a16z).Open the full entry, a general partner on the Bio + Health team at Andreessen Horowitz (a16z), spoke with Bancel; the corresponding a16z.com episode page is titled “Inside Moderna’s Personalized Cancer Vaccine.”⁠[7][8]

The conversation centered on the Phase 3 results of Moderna and Merck & Co.’s individualized melanoma treatment. Bancel explained how it works: sequencing a patient’s tumor and healthy cells, identifying the most relevant mutations and encoding up to 34 of them in a patient-specific mRNA to teach the immune system what to attack. They also discussed the manufacturing challenge of making a different medicine for each patient, including how Moderna reduced the process to about 42 days from biopsy to treatment, what scaling would require and the regulatory questions involved.⁠[8][7]

Bancel also discussed potential applications in lung, kidney, bladder, pancreatic and gastric cancers, and Moderna’s longer-term work applying mRNA to rare genetic and autoimmune diseases.⁠[8]

Bancel serves on the board of Generate BiomedicinesGenerate BiomedicinesGenerate Biomedicines is a US biotechnology company combining machine learning, biological engineering and experimental research to design protein medicines. Its platform connects computationally generated candidates with experimental data to advance work across therapeutic areas and protein modalities.Open the full entry; Flagship Pioneering’s profile also lists him as a board member of Indigo Ag, both companies founded by Flagship.⁠[2][4]

Moderna: Official website: https://www.modernatx.com/ (opens in a new window).⁠[2]

Flagship Pioneering: Official website: https://www.flagshippioneering.com/ (opens in a new window).⁠[4]